Related Experiment Video

Updated: Jun 23, 2026

A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings
06:59

A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings

Published on: November 9, 2016

Medicare program: Medicare Advantage and prescription drug programs MIPPA drug formulary & protected classes

    Federal Register
    |April 24, 2009
    PubMed

    Insights

    This rule updates Medicare prescription drug benefit (Part D) regulations. Changes reflect the Medicare Improvements for Patients and Providers Act (MIPPA), altering covered drug definitions and formulary requirements.

    Area of Science:

    • Health Policy
    • Pharmaceutical Regulation
    • Medicare

    Background:

    • The Medicare prescription drug benefit program, known as Part D, has undergone regulatory updates.
    • Previous regulations required adjustments to align with legislative changes.

    Purpose of the Study:

    • To revise existing regulations for the Medicare Part D program.
    • To implement conforming changes mandated by the Medicare Improvements for Patients and Providers Act (MIPPA).

    Main Methods:

    • Analysis of the Medicare Improvements for Patients and Providers Act (MIPPA) provisions.
    • Revision of existing regulatory text governing the Medicare Part D program.

    Main Results:

    • The definition of a covered Part D drug has been modified.
    • New requirements for Part D formularies have been introduced.

    Conclusions:

    • The updated regulations ensure compliance with MIPPA.
    • These changes impact the scope of covered drugs and formulary management within Medicare Part D.

    More Related Videos

    Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index06:55

    Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index

    Published on: January 8, 2020

    Related Concept Videos

    FDA Approved Drugs: Changes to Approved Drugs01:26

    FDA Approved Drugs: Changes to Approved Drugs

    Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
    Drug Products: Biologics, Biosimilars and Interchangeables01:28

    Drug Products: Biologics, Biosimilars and Interchangeables

    Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
    Prescription, Nonprescription and Orphan Drugs01:02

    Prescription, Nonprescription and Orphan Drugs

    Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
    The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
    Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

    Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

    PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
    Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

    Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

    Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
    Dosage Regimens: Partial Pharmacokinetic Parameters01:01

    Dosage Regimens: Partial Pharmacokinetic Parameters

    It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...